©NIJRMS
Publications 2025

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

NEWPORT INTERNATIONAL JOURNAL OF RESEARCH IN MEDICAL SCIENCES (NIJRMS)

Volume 7 Issue 1 Page 25-30, 2026

https://doi.org/10.59298/NIJRMS/2026/7.1.2530

Nanoparticle Mediated Modulation of Adipose Tissue Inflammation in Obesity-Induced Insulin Resistance

Kamanzi Ntakirutimana G.

School of Natural and Applied Sciences Kampala International University Uganda

ABSTRACT

Obesity-induced insulin resistance (IR) is a major contributor to the pathogenesis of type 2 diabetes (T2D) and is largely driven by chronic low-grade inflammation in adipose tissue. Adipose tissue inflammation not only impairs insulin signaling but also exacerbates metabolic disturbances by promoting systemic inflammation. Nanotechnology offers innovative approaches to modulate adipose tissue inflammation and improve insulin sensitivity. Nanoparticles (NPs), due to their small size, high surface area, and ability to carry bioactive molecules, can target adipose tissue and specifically reduce inflammation at the molecular level. This review discusses various nanoparticle-mediated strategies for modulating adipose tissue inflammation in obesity-induced insulin resistance, including the use of anti-inflammatory drugs, natural compounds, and RNA-based therapies. We explore the mechanisms by which nanoparticles enhance drug delivery, their impact on insulin sensitivity, and their potential therapeutic applications. Additionally, the challenges and future perspectives for the clinical translation of these nanotechnologies are highlighted.

Keywords: obesity, insulin resistance, adipose tissue inflammation, nanoparticles, drug delivery

INTRODUCTION

Obesity, characterized by excessive fat accumulation in adipose tissue, has emerged as one of the leading global health concerns, with a significant association to the development of insulin resistance (IR) and type 2 diabetes (T2D). In obesity, adipose tissue undergoes structural and functional alterations, leading to adipocyte hypertrophy, altered adipokine secretion, and the infiltration of immune cells, which collectively promote a state of chronic low-grade inflammation[1–4]. This inflammatory milieu within adipose tissue plays a crucial role in the development of insulin resistance by interfering with insulin signaling pathways, impairing glucose uptake, and promoting systemic inflammation that further exacerbates metabolic disturbances[5–7].

Adipose tissue inflammation is a critical component of obesity-induced IR. The expansion of adipocytes in obese individuals results in hypoxia, oxidative stress, and cellular stress, which in turn trigger inflammatory responses involving immune cells such as macrophages, T cells, and neutrophils[3, 8–10]. These cells release pro-inflammatory cytokines like TNF-α, IL-6, and IL-1β, which not only impair insulin receptor signaling but also increase the secretion of inflammatory adipokines such as resistin and leptin. These processes create a vicious cycle of inflammation, leading to worsening insulin resistance and the development of metabolic diseases[5, 11–13].

Current therapeutic strategies for combating obesity-induced insulin resistance largely focus on lifestyle modifications (diet and exercise) and pharmacological interventions aimed at improving insulin sensitivity[14, 15]. However, these approaches often fail to effectively target adipose tissue inflammation at a molecular level and tend to have limited efficacy. The need for more effective, targeted therapies has driven research into the use of nanotechnology, specifically nanoparticles (NPs) as a potential solution.

Nanoparticles are ultra-small carriers, typically ranging from 1 to 100 nm, that have unique properties, such as high surface area, biocompatibility, and the ability to carry and deliver a wide variety of therapeutic agents[14–17]. The small size of NPs allows for improved cellular uptake, enhanced bioavailability, and targeted delivery of drugs to specific tissues, such as adipose tissue. This makes NPs particularly attractive for addressing the challenges of treating adipose tissue inflammation and insulin resistance[18–21]. Nanoparticles can be

engineered to carry anti-inflammatory drugs, natural compounds, or gene therapies that specifically modulate the inflammatory pathways involved in obesity-induced insulin resistance.

One of the key advantages of using nanoparticles in this context is their ability to improve the targeted delivery of therapeutics directly to adipose tissue, minimizing off-target effects and reducing the required dosages of active agents[22–24]. Furthermore, NPs can be modified with specific ligands or surface coatings to enhance their selectivity for inflamed adipose tissue, where inflammation-related receptors or markers are upregulated. For instance, targeting scavenger receptors (such as CD36) or macrophage surface markers allows for the selective delivery of nanoparticles to the sites of inflammation, ensuring that the therapeutic agents act directly on the source of the problem. This review will delve into various strategies involving nanoparticle-mediated delivery systems to modulate adipose tissue inflammation in obesity-induced insulin resistance. We will discuss the types of nanoparticles used, the mechanisms of action, and their effectiveness in improving insulin sensitivity and reducing inflammatory markers in adipose tissue. Additionally, we will highlight the challenges in the translation of these nanoparticle-based therapies into clinical practice and outline future directions for research in this field.

2. Nanoparticle Types and Mechanisms of Action

Nanoparticles (NPs) can be designed from a wide range of materials, including lipids, polymers, metals, and proteins, each offering distinct advantages for targeting adipose tissue inflammation in obesity-induced insulin resistance. These materials can be modified for controlled drug release, stability, and enhanced targeting to adipose tissue macrophages or adipocytes.

Lipid-Based Nanoparticles

Lipid-based nanoparticles, such as liposomes, solid lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs), are among the most commonly used platforms for delivering anti-inflammatory drugs or natural compounds. Liposomes are spherical vesicles composed of lipid bilayers, capable of encapsulating both hydrophilic and hydrophobic drugs[25]. These nanoparticles have demonstrated excellent biocompatibility and can efficiently deliver anti-inflammatory agents like curcumin or resveratrol to adipose tissue, where they reduce the secretion of pro-inflammatory cytokines such as TNF-α and IL-6.

SLNs and NLCs are similar to liposomes but are composed of solid lipids. These particles offer better physical stability and are less prone to oxidation compared to liposomes. NLCs, in particular, provide enhanced drug-loading capacity, making them ideal for the delivery of bioactive agents that can modulate inflammation in obese adipose tissue[26, 27].

Polymeric Nanoparticles

Polymeric nanoparticles are fabricated using biodegradable polymers such as poly(lactic-co-glycolic acid) (PLGA), chitosan, and polyethylene glycol (PEG)[28–31]. These nanoparticles offer a controlled release of the encapsulated drug, ensuring sustained therapeutic effects over time. PLGA-based nanoparticles have been widely used to deliver anti-inflammatory drugs like glucocorticoids or metformin, both of which have shown promise in improving insulin sensitivity in obese animal models by reducing adipose tissue inflammation[30]. Chitosan, a natural polymer, can also be used to form nanoparticles that target macrophages within adipose tissue, further enhancing their anti-inflammatory effects.

Metal Nanoparticles

Metal nanoparticles, including gold nanoparticles (AuNPs) and silver nanoparticles (AgNPs), have gained attention for their antioxidant and anti-inflammatory properties[23, 23, 32, 33]. These nanoparticles can be functionalized with ligands to enhance their specificity for inflamed adipose tissue. AuNPs, for example, have been shown to reduce oxidative stress in adipocytes, thereby decreasing the activation of inflammatory pathways like NF-κB[30]. Silver nanoparticles can interact with macrophages in adipose tissue, reducing the secretion of pro-inflammatory cytokines and restoring insulin sensitivity.

Mechanisms of Action

Nanoparticles can modulate adipose tissue inflammation via multiple mechanisms. First, they can target macrophages within adipose tissue, reducing their pro-inflammatory activity. Second, they can influence adipocyte function by modulating adipokine secretion or reducing oxidative stress[34, 35]. Additionally, nanoparticles can be engineered to release their payload in a glucose-responsive manner or in response to inflammatory stimuli, ensuring that therapeutic agents are released when inflammation is at its peak. Moreover, nanoparticles can also alter the immune microenvironment within adipose tissue by promoting the polarization of M2 macrophages (anti-inflammatory phenotype) over M1 macrophages (pro-inflammatory phenotype), thus reducing overall tissue inflammation and improving insulin signaling[34].

3. Role of Nanoparticles in Modulating Insulin Sensitivity

The ultimate goal of nanoparticle-mediated therapies in obesity-induced insulin resistance (IR) is to restore insulin sensitivity by reducing the chronic inflammation in adipose tissue. Obesity leads to an imbalance in adipose tissue homeostasis, resulting in adipocyte hypertrophy, macrophage infiltration, and an increase in pro-inflammatory cytokines[36]. This inflammatory state is a major contributor to the development of insulin resistance by impairing insulin receptor signaling and disrupting glucose uptake[36].

Improving Insulin Receptor Signaling

Nanoparticles loaded with anti-inflammatory agents can restore insulin receptor signaling pathways by modulating the expression of key proteins involved in insulin action[37]. For instance, curcumin-loaded nanoparticles have been shown to improve insulin sensitivity in obese animal models by reducing TNF-α levels and increasing IRS-1 (insulin receptor substrate 1) expression. By decreasing the inflammatory cytokine milieu, these nanoparticles facilitate glucose uptake in adipose tissue and other insulin-sensitive organs, such as skeletal muscle and liver[38].

Enhancing Adipocyte Function

In addition to modulating insulin receptor signaling, nanoparticles can directly target adipocytes to improve their function. Polymeric nanoparticles loaded with compounds like resveratrol have been shown to reduce oxidative stress in adipocytes, leading to a decrease in lipid accumulation and adipocyte hypertrophy[28, 30]. This results in improved insulin sensitivity in adipose tissue and reduced systemic inflammation, both of which contribute to better overall metabolic control. Moreover, nanoparticles can also enhance mitochondrial function in adipocytes, thereby improving energy expenditure and fat oxidation, processes that are typically impaired in obese individuals[39, 40]. This can lead to a reduction in visceral fat and an overall improvement in insulin sensitivity.

Reducing Systemic Inflammation

The effects of nanoparticles are not limited to adipose tissue alone. By targeting the root cause of obesity-induced insulin resistance adipose tissue inflammation nanoparticles can also reduce systemic inflammation[41]. By decreasing the levels of circulating pro-inflammatory cytokines, such as IL-6 and CRP, nanoparticle-based therapies have the potential to improve insulin sensitivity not only in adipose tissue but also in the liver and skeletal muscle, which are critical for glucose homeostasis.

4. Preclinical and Clinical Outcomes

The application of nanoparticles to modulate adipose tissue inflammation and improve insulin sensitivity has been investigated in numerous preclinical studies[42]. These studies have provided valuable insights into the potential of nanoparticle-based therapies for treating obesity-induced insulin resistance[42, 43].

Preclinical Studies

In animal models of obesity and insulin resistance, nanoparticle-based drug delivery systems have been shown to significantly reduce adipose tissue inflammation and improve insulin sensitivity[44]. For example, liposomal curcumin administered to obese rats reduced adipose tissue macrophage infiltration and the expression of pro-inflammatory cytokines like TNF-α and IL-6. These changes were associated with an improvement in insulin signaling, including increased phosphorylation of the insulin receptor and enhanced glucose uptake in adipocytes[44].

Similarly, PLGA nanoparticles loaded with metformin or rosiglitazone, two common drugs used to treat insulin resistance, have demonstrated significant improvements in insulin sensitivity and a reduction in visceral fat accumulation[45]. These results highlight the ability of nanoparticles to enhance the delivery and efficacy of therapeutic agents that modulate adipose tissue inflammation and insulin resistance[45].

Clinical Studies

While clinical trials investigating nanoparticle-based therapies for obesity-induced insulin resistance are still in the early stages, preliminary studies have shown promising results[46]. In human trials, liposomal formulations of curcumin and resveratrol have demonstrated increased bioavailability, reduced inflammation, and improved insulin sensitivity in obese individuals. These results suggest that nanoparticle-mediated therapies may offer a viable approach to targeting adipose tissue inflammation and improving metabolic control in humans[46].

5. Challenges and Future Directions

Despite the promising preclinical data, the clinical translation of nanoparticle-based therapies for obesity-induced insulin resistance faces several challenges.

Biocompatibility and Safety

The biocompatibility of nanoparticles is a primary concern, particularly when used for long-term treatment[47]. While many nanoparticles are designed to be biodegradable, the potential for immune responses or toxicity upon accumulation in tissues must be carefully evaluated. Systemic toxicity, immunogenicity, and inflammatory responses triggered by nanoparticles may pose significant barriers to their widespread clinical use[47].

Manufacturing and Scalability

The large-scale production of nanoparticles that meet clinical standards is another challenge. Ensuring reproducibility, consistent drug-loading, and scalable production methods for nanoparticles remains a significant hurdle for their commercialization[48].

Future Directions

Future research should focus on developing nanoparticles that can target adipose tissue more specifically, potentially by using ligand-receptor interactions to increase targeting specificity. Additionally, combination therapies, where nanoparticles deliver anti-inflammatory drugs alongside other therapeutic agents like insulin sensitizers, could enhance the overall therapeutic effect. Lastly, clinical trials that assess long-term safety,

efficacy, and optimal dosages of nanoparticle-based therapies will be crucial in determining their potential as mainstream treatments for obesity-induced insulin resistance.

CONCLUSION

Nanoparticles offer a promising approach for addressing the chronic inflammation that underlies obesity-induced insulin resistance. By enhancing the delivery of anti-inflammatory drugs or natural compounds, nanoparticles can directly target adipose tissue, reducing inflammation, improving insulin signaling, and enhancing metabolic control. Preclinical studies have demonstrated the potential of nanoparticles to reduce adipose tissue inflammation and improve insulin sensitivity, while early clinical trials suggest that these technologies can be safely and effectively applied to human patients. However, significant challenges remain in terms of biocompatibility, scalability, and long-term safety. As research progresses, novel nanoparticle formulations with improved targeting, stability, and therapeutic efficacy are likely to emerge. Ultimately, nanoparticle-mediated therapies hold the potential to revolutionize the treatment of obesity-induced insulin resistance, offering more effective and targeted approaches to managing this global epidemic.

REFERENCES

1. Acevedo-Román, A., Pagán-Zayas, N., Velázquez-Rivera, L.I., Torres-Ventura, A.C., Godoy-Vitorino, F.: Insights into Gut Dysbiosis: Inflammatory Diseases, Obesity, and Restoration Approaches. Int. J. Mol. Sci. 25, 9715 (2024). https://doi.org/10.3390/ijms25179715
2. Aloo, S.O., Barathikannan, K., Oh, D.-H.: Polyphenol-rich fermented hempseed ethanol extracts improve obesity, oxidative stress, and neural health in high-glucose diet-induced *Caenorhabditis elegans*. Food Chem. X. 21, 101233 (2024). https://doi.org/10.1016/j.fochx.2024.101233
3. Anguita-Ruiz, A., Bustos-Aibar, M., Plaza-Díaz, J., Mendez-Gutierrez, A., Alcalá-Fdez, J., Aguilera, C.M., Ruiz-Ojeda, F.J.: Omics Approaches in Adipose Tissue and Skeletal Muscle Addressing the Role of Extracellular Matrix in Obesity and Metabolic Dysfunction. Int. J. Mol. Sci. 22, 2756 (2021). https://doi.org/10.3390/ijms22052756
4. Izah, S.C., Betiang, P.A., Paul-Chima Ugwu, O., Ainebyoona, C., Uti, D.E., Echegu, D.A., Alum, B.N.: The Ketogenic Diet in Obesity Management: Friend or Foe? Cell Biochem. Biophys. (2025). https://doi.org/10.1007/s12013-025-01878-0
5. Rohm, T.V., Meier, D.T., Olefsky, J.M., Donath, M.Y.: Inflammation in obesity, diabetes, and related disorders. Immunity. 55, 31–55 (2022). https://doi.org/10.1016/j.immuni.2021.12.013
6. Zhao, X., An, X., Yang, C., Sun, W., Ji, H., Lian, F.: The crucial role and mechanism of insulin resistance in metabolic disease. Front. Endocrinol. 14, (2023). https://doi.org/10.3389/fendo.2023.1149239
7. Berbudi, A., Khairani, S., Tjahjadi, A.I.: Interplay Between Insulin Resistance and Immune Dysregulation in Type 2 Diabetes Mellitus: Implications for Therapeutic Interventions. ImmunoTargets Ther. 14, 359–382 (2025). https://doi.org/10.2147/ITT.S499605
8. Auger, C., Kajimura, S.: Adipose Tissue Remodeling in Pathophysiology. Annu. Rev. Pathol. Mech. Dis. 18, 71–93 (2023). https://doi.org/10.1146/annurev-pathol-042220-023633
9. Daley, A.D., Bénézech, C.: Fat-associated lymphoid clusters: Supporting visceral adipose tissue B cell function in immunity and metabolism. Immunol. Rev. 324, 78–94 (2024). https://doi.org/10.1111/imr.13339
10. de Sousa Neto, I.V., Durigan, J.L.Q., da Silva, A.S.R., de Cássia Marqueti, R.: Adipose Tissue Extracellular Matrix Remodeling in Response to Dietary Patterns and Exercise: Molecular Landscape, Mechanistic Insights, and Therapeutic Approaches. Biology. 11, 765 (2022). https://doi.org/10.3390/biology11050765
11. Alharbi, H.O.A., Alshebremi, M., Babiker, A.Y., Rahmani, A.H.: The Role of Quercetin, a Flavonoid in the Management of Pathogenesis Through Regulation of Oxidative Stress, Inflammation, and Biological Activities. Biomolecules. 15, 151 (2025). https://doi.org/10.3390/biom15010151
12. Bhat, A.A., Uppada, S., Achkar, I.W., Hashem, S., Yadav, S.K., Shanmugakonar, M., Al-Naemi, H.A., Haris, M., Uddin, S.: Tight Junction Proteins and Signaling Pathways in Cancer and Inflammation: A Functional Crosstalk. Front. Physiol. 9, 1942 (2019). https://doi.org/10.3389/fphys.2018.01942
13. Obasi, D.C., Abba, J.N., Aniokete, U.C., Okoroh, P.N., Akwari, A.Ak.: Evolving Paradigms in Nutrition Therapy for Diabetes: From Carbohydrate Counting to Precision Diets. Obes. Med. 100622 (2025). https://doi.org/10.1016/j.obmed.2025.100622
14. Uti, D.E., Atangwho, I.J., Omang, W.A., Alum, E.U., Obeten, U.N., Udeozor, P.A., Agada, S.A., Bawa, I., Ogbu, C.O.: Cytokines as key players in obesity low grade inflammation and related complications. Obes. Med. 54, 100585 (2025). https://doi.org/10.1016/j.obmed.2025.100585
15. Moghbeli, M., Khedmatgozar, H., Yadegari, M., Avan, A., Ferns, G.A., Ghayour Mobarhan, M.: Cytokines and the immune response in obesity-related disorders. Adv. Clin. Chem. 101, 135–168 (2021). https://doi.org/10.1016/bs.acc.2020.06.004
16. Liu, H., Su, Y.-Y., Jiang, X.-C., Gao, J.-Q.: Cell membrane-coated nanoparticles: a novel multifunctional biomimetic drug delivery system. Drug Deliv. Transl. Res. 13, 716–737 (2023). https://doi.org/10.1007/s13346-022-01252-0

17. Omang, W.A., Ugwu, O.P.-C., Wokoma, M.A., Oplekwu, R.I., Atangwho, I.J., Egbung, G.E.: Combined Hyaluronic Acid Nanobioconjugates Impair CD44-Signaling for Effective Treatment Against Obesity: A Review of Comparison with Other Actors. Int. J. Nanomedicine. 20, 10101–10126 (2025). https://doi.org/10.2147/IJN.S529250
18. Farzin, A., Etesami, S.A., Quint, J., Memic, A., Tamayol, A.: Magnetic nanoparticles in cancer therapy and diagnosis. Adv. Healthc. Mater. 9, e1901058 (2020). https://doi.org/10.1002/adhm.201901058
19. Ahmar, H.: Nonenzymatic Electrochemical Detection of Glucose Using Screen-Printed Electrode Modified with Pd–Au Nanoparticles Encapsulated on Dendrimer Grafted Multi-Wall Carbon Nanotubes. Curr. Appl. Sci. 2, 67–78 (2024). https://doi.org/10.22034/cas.2022.343533.1019
20. Barua, S., Mitragotri, S.: Challenges associated with Penetration of Nanoparticles across Cell and Tissue Barriers: A Review of Current Status and Future Prospects. Nano Today. 9, 223–243 (2014). https://doi.org/10.1016/j.nantod.2014.04.008
21. Chen, Z., Krishnamachary, B., Pachecho-Torres, J., Penet, M.-F., Bhujwalla, Z.M.: Theranostic small interfering RNA nanoparticles in cancer precision nanomedicine. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 12, e1595 (2020). https://doi.org/10.1002/wnan.1595
22. Ghandforoushan, P., Hanaee, J., Aghazadeh, Z., Samiei, M., Navali, A.M., Khatibi, A., Davaran, S.: Enhancing the function of PLGA-collagen scaffold by incorporating TGF-β1-loaded PLGA-PEG-PLGA nanoparticles for cartilage tissue engineering using human dental pulp stem cells. Drug Deliv. Transl. Res. 12, 2960–2978 (2022). https://doi.org/10.1007/s13346-022-01161-2
23. Munderere, R., Gulfam, M., Ali, I., Kim, S.-H., Vu, T.T., Park, S.-H., Lim, K.T.: Redox-Responsive Gold Nanoparticles Coated with Hyaluronic Acid and Folic Acid for Application in Targeting Anticancer Therapy. Molecules. 29, 1564 (2024). https://doi.org/10.3390/molecules29071564
24. Long, Q., Liu, Z., Shao, Q., Shi, H., Huang, S., Jiang, C., Qian, B., Zhong, Y., He, X., Xiang, X., Yang, Y., Li, B., Yan, X., Zhao, Q., Wei, X., Santos, H.A., Ye, X.: Autologous Skin Fibroblast-Based PLGA Nanoparticles for Treating Multiorgan Fibrosis. Adv. Sci. 9, 2200856 (2022). https://doi.org/10.1002/advs.202200856
25. Gabel, M., Knauss, A., Fischer, D., Neurath, M.F., Weigmann, B.: Surface Design Options in Polymer- and Lipid-Based siRNA Nanoparticles Using Antibodies. Int. J. Mol. Sci. 23, 13929 (2022). https://doi.org/10.3390/ijms232213929
26. Mehta, A.: Managing dyslipidemia in solid organ transplant patients. Indian Heart J. 76, S93–S95 (2024). https://doi.org/10.1016/j.ihj.2024.01.004
27. Wang, W., Zhou, M., Xu, Y., Peng, W., Zhang, S., Li, R., Zhang, H., Zhang, H., Cheng, S., Wang, Y., Wei, X., Yue, C., Yang, Q., Chen, C.: Resveratrol-Loaded TPGS-Resveratrol-Solid Lipid Nanoparticles for Multidrug-Resistant Therapy of Breast Cancer: In Vivo and In Vitro Study. Front. Bioeng. Biotechnol. 9, 762489 (2021). https://doi.org/10.3389/fbioe.2021.762489
28. Begines, B., Ortiz, T., Pérez-Aranda, M., Martínez, G., Merinero, M., Argüelles-Arias, F., Alcudia, A.: Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects. Nanomaterials. 10, 1403 (2020). https://doi.org/10.3390/nano10071403
29. kapoor, D. u, Garg, R., Gaur, M., Prajapati, B.G., Agrawal, G., Bhattacharya, S., Elossaily, G.M.: Polymeric nanoparticles approach and identification and characterization of novel biomarkers for colon cancer. Results Chem. 6, 101167 (2023). https://doi.org/10.1016/j.rechem.2023.101167
30. Wang, X.-Q., Zhang, Q.: pH-sensitive polymeric nanoparticles to improve oral bioavailability of peptide/protein drugs and poorly water-soluble drugs. Eur. J. Pharm. Biopharm. 82, 219–229 (2012). https://doi.org/10.1016/j.ejpb.2012.07.014
31. Zhang, W., Mehta, A., Tong, Z., Esser, L., Voelcker, N.H.: Development of Polymeric Nanoparticles for Blood–Brain Barrier Transfer—Strategies and Challenges. Adv. Sci. 8, 2003937 (2021). https://doi.org/10.1002/advs.202003937
32. Li, W., Chen, X.: Gold nanoparticles for photoacoustic imaging. Nanomed. 10, 299–320 (2015). https://doi.org/10.2217/nnm.14.169
33. Alum, E.U., Nwuruku, O.A., Ugwu, O.P.-C., Uti, D.E., Alum, B.N., Edwin, N.: Harnessing nature: plant-derived nanocarriers for targeted drug delivery in cancer therapy. Phytomedicine Plus. 5, 100828 (2025). https://doi.org/10.1016/j.phyplu.2025.100828
34. Bensussen, A., Torres-Magallanes, J.A., Roces De Álvarez-Buylla, E.: Molecular tracking of insulin resistance and inflammation development on visceral adipose tissue. Front. Immunol. 14, 1014778 (2023). https://doi.org/10.3389/fimmu.2023.1014778
35. Divella, R., De Luca, R., Abbate, I., Naglieri, E., Daniele, A.: Obesity and cancer: the role of adipose tissue and adipo-cytokines-induced chronic inflammation. J. Cancer. 7, 2346–2359 (2016). https://doi.org/10.7150/jca.16884
36. Queiroz, M., Sena, C.M.: Perivascular adipose tissue: a central player in the triad of diabetes, obesity, and cardiovascular health. Cardiovasc. Diabetol. 23, 455 (2024). https://doi.org/10.1186/s12933-024-02549-9

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

37. Priya, Chaudhary, A., Rejeeth, C., Kumar, S., Ding, X., Sharma, A.: Exploring plant-based metallic nanoparticles for advanced medicinal application in diabetes. Nanotechnol. 8, 100243 (2025). https://doi.org/10.1016/j.nxnano.2025.100243
38. Attri, K., Chudasama, B., Mahajan, R.L., Choudhury, D.: Integrated insulin-iron nanoparticles: a multi-modal approach for receptor-specific bioimaging, reactive oxygen species scavenging, and wound healing. Discov. Nano. 19, 96 (2024). https://doi.org/10.1186/s11671-024-04024-6
39. Janib, S.M., Moses, A.S., MacKay, J.A.: Imaging and drug delivery using theranostic nanoparticles. Adv. Drug Deliv. Rev. 62, 1052–1063 (2010). https://doi.org/10.1016/j.addr.2010.08.004
40. Shaban, E.E., Abd El-Aziz, M.E.: Innovative nanotechnological approaches to diabetes treatment: the role of metal oxide nanoparticles. Pharm. Dev. Technol. 30, 1227–1249 (2025). https://doi.org/10.1080/10837450.2025.2566460
41. Wang, L., Chen, J., Li, J., Zhang, J., Zou, M., Liu, Q., Jing, X., Jia, Q., Li, J., Zhang, Z., Zhang, Z., He, J., Li, Y.: A two-pronged nanomedicine counteracts obesity by remodeling adipose niche. J. Controlled Release. 114387 (2025). https://doi.org/10.1016/j.jconrel.2025.114387
42. Wang, L., Jia, Q., He, J., Li, Y.: Adipose tissue-targeting nanomedicines for obesity pharmacotherapy. Trends Endocrinol. Metab. (2025). https://doi.org/10.1016/j.tem.2025.03.010
43. Bakshi, V., Fathima, B.: Solid Lipid Nanoparticles in Metabolic Disorders: A Novel Strategy for Targeted Delivery in Diabetes and Obesity. J. Bio-X Res. 8, 0066 (2025). https://doi.org/10.34133/jbioxresearch.0066
44. Liu, M., Wang, R., Hoi, M.P.M., Wang, Y., Wang, S., Li, G., Vong, C.T., Chong, C.-M.: Nano-Based Drug Delivery Systems for Managing Diabetes: Recent Advances and Future Prospects. Int. J. Nanomedicine. 20, 6221–6252 (2025). https://doi.org/10.2147/IJN.S508875
45. Pereira, A. de S.B.F., Brito, G.A. de C., Lima, M.L. de S., Silva Júnior, A.A. da, Silva, E. dos S., De Rezende, A.A., Bortolin, R.H., Galvan, M., Pirih, F.Q., Araújo Júnior, R.F. de, Medeiros, C.A.C.X. de, Guerra, G.C.B., Araújo, A.A. de: Metformin Hydrochloride-Loaded PLGA Nanoparticle in Periodontal Disease Experimental Model Using Diabetic Rats. Int. J. Mol. Sci. 19, 3488 (2018). https://doi.org/10.3390/ijms19113488
46. El-Araby, R.E., Tu, Q., Xie, Y., Aboushousha, T., Li, Z., Xu, X., Zhu, Z.X., Dong, L.Q., Chen, J.: Adiponectin mRNA Conjugated with Lipid Nanoparticles Specifically Targets the Pathogenesis of Type 2 Diabetes. Aging Dis. 16, 1059–1079 (2024). https://doi.org/10.14336/AD.2024.0162
47. Kyriakides, T.R., Raj, A., Tseng, T.H., Xiao, H., Nguyen, R., Mohammed, F.S., Halder, S., Xu, M., Wu, M.J., Bao, S., Sheu, W.C.: Biocompatibility of nanomaterials and their immunological properties. Biomed. Mater. Bristol Engl. 16, 10.1088/1748-605X/abe5fa (2021). https://doi.org/10.1088/1748-605X/abe5fa
48. Costa, C., Padrela, L.: Progress on drug nanoparticle manufacturing: exploring the adaptability of batch bottom-up approaches to continuous manufacturing. J. Drug Deliv. Sci. Technol. 111, 107120 (2025). https://doi.org/10.1016/j.jddst.2025.107120

CITE AS: Kamanzi Ntakirutimana G. (2026). Nanoparticle Mediated Modulation of Adipose Tissue Inflammation in Obesity-Induced Insulin Resistance. NEWPORT INTERNATIONAL JOURNAL OF RESEARCH IN MEDICAL SCIENCES. https://doi.org/10.59298/NIJRMS/2026/7.1.2530